{
  "source": "PA-Med-Nec-Movantik.txt",
  "chunks": [
    "United Healthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2147-7\nProgram Prior Authorization/Medical Necessity\nMedication Movantik® (naloxegol)*\nP&T Approval Date 7/2018, 7/2019, 8/2020, 6/2021, 6/2022, 6/2023, 6/2024\nEffective Date 9/1/2024\n1. Background:\nMovantik (naloxegol)* and Symproic® (naldemedine) are opioid antagonists indicated for the\ntreatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain\nincluding patients with chronic pain related to prior cancer or its treatment who do not require\nfrequent (e.g., weekly) opioid dosage escalation. Amitiza®* (lubiprostone) is indicated for the\ntreatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in\nadults and for the treatment opioid-induced constipation (OIC) in adult patients with chronic,\nnon-cancer pain, including patients with chronic pain related to prior cancer or its treatment who\ndo not require frequent (e.g., weekly) opioid dosage escalation.\nThis prior authorization program is intended to encourage the use of lower cost alternatives. This\nprogram requires a member lower cost alternatives before providing coverage for Movantik.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Movantik* will be approved based on BOTH of the following:\na. ONE of the following:\n(1) Diagnosis of opioid-induced constipation with chronic, non-cancer pain\n-OR-\n(2) Diagnosis of opioid-induced constipation in patients with chronic pain related to\nprior cancer diagnosis or cancer treatment who do not require frequent (e.g.,\nweekly) opioid dosage escalation\n-AND-\nb. History of failure, contraindication or intolerance to BOTH of the following\n(document date tried):\n(1) lubiprostone (generic Amitiza)\n-AND-\n(2) Symproic\nAuthorization will be issued for 12 months\n© 2024 UnitedHealthcare Services Inc.\n1\nB. Reauthorization\n1. Movantik* will be approved based on the following criterion:\na. Documentation of positive clinical response to Movantik* the",
    "for 12 months\n© 2024 UnitedHealthcare Services Inc.\n1\nB. Reauthorization\n1. Movantik* will be approved based on the following criterion:\na. Documentation of positive clinical response to Movantik* therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Brand only Amitiza and Movantik are typically excluded from coverage\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n• Notification/Prior Authorization may be in place.\n4. References:\n1. Amitiza [package insert]. Lexington, MA: Takeda pharmaceuticals America, Inc; November\n2020.\n2. Movantik [package insert]. Chicago, IL: Valinor Pharma, LLC; March 2023.\n3. Symproic [package insert]. Raleigh, NC: BioDelivery Sciences International; July 2021.\nProgram Prior Authorization/Medical Necessity – Movantik\nChange Control\nDate Change\n7/2018 New program.\n7/2019 Annual review. No changes.\n8/2020 Annual review. Updated initial authorization and references.\n6/2021 Annual review. Updated references.\n6/2022 Annual review. Updated references.\n6/2023 Annual review. Updated references. Removed OTC step and added\nstep through generic Amitiza.\n6/2024 Annual review. Updated background section. Added document date\ntried. Referenced brand Amitiza exclusion. Updated references.\n© 2024 UnitedHealthcare Services Inc.\n2"
  ]
}